Anne-Marie Stoppa

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Philippe Moreau, Tamás Masszi, Norbert Grząśko et al. · New England Journal of Medicine · 2016 · 1.1K citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Aurore Perrot, Valérie Lauwers‐Cancès, Jill Corre et al. · Blood · 2018 · 420 citations · Full text

Medicine, Hematology, Oncology +15

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

Marie‐Lorraine Chrétien, Jill Corre, Valérie Lauwers‐Cancès et al. · Blood · 2015 · 115 citations

Life Sciences, Genetics, Oncology +12

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

Benjamin Hébraud, Florence Magrangeas, Alice Cleynen et al. · Blood · 2015 · 97 citations · Full text

Life Sciences, Genetics, Hematology +13

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Anaïs Schavgoulidze, Alexis Talbot, Aurore Perrot et al. · Blood · 2022 · 62 citations · Full text

Medicine, Hematology, Oncology +8